Precision Oncology & Cancer Genomics
Identify actionable tumour mutations and structural variants through comprehensive genomic profiling. We provide vital insights, such as Tumor Mutational Burden (TMB), to guide targeted cancer therapies and precision immunotherapy.
Consult With Our Experts
Overview
Precision Oncology represents a paradigm shift in cancer care, moving away from a "one-size-fits-all" approach to highly individualized treatment strategies. By utilizing comprehensive genomic profiling, we identify specific actionable tumor mutations and structural variants that drive malignancy. Our analysis provides critical clinical insights, such as Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI), which are essential for guiding targeted therapies and precision immunotherapy. This data-driven methodology ensures that oncologists can select the most effective interventions while sparing patients from the toxicity of ineffective treatments.
Key Features
> Comprehensive Genomic Profiling (CGP): Detecting all classes of genomic alterations in a single assay.
> Targeted Therapy Matching: Aligning patient-specific mutations with FDA-approved or late-stage clinical trial drugs.
> Immunotherapy Biomarkers: Evaluating TMB and PD-L1 status to predict response to checkpoint inhibitors.
> Liquid Biopsy Capabilities: Monitoring tumor evolution and minimal residual disease (MRD) through non-invasive blood draws.
> Structural Variant Analysis: Identifying complex rearrangements and copy number variations (CNVs) that traditional tests might miss.
Application & Demo
In a recent clinical collaboration, we performed genomic profiling on a cohort of late-stage non-small cell lung cancer (NSCLC) patients who had exhausted standard care options. By applying our high-depth sequencing pipeline, we identified rare ALK and ROS1 rearrangements in several patients that were previously undetected. This insight allowed for the administration of targeted tyrosine kinase inhibitors (TKIs), resulting in significant tumor shrinkage and a 45% increase in progression-free survival (PFS) compared to the standard chemotherapy group.
Frequently Asked Questions
How does Precision Oncology differ from traditional oncology?
Traditional oncology treats cancer based on its location (e.g., lung, breast), whereas precision oncology treats it based on the specific genetic "blueprint" of the tumor.
What is Tumor Mutational Burden (TMB)?
TMB measures the number of mutations within a tumor's genome; higher TMB often indicates a better response to immunotherapy.
Can this service be used for all types of cancer?
Yes, it is applicable to both solid tumors and hematological malignancies (blood cancers).
How long does the analysis take?
Our standard clinical turnaround time is 10 to 14 business days from the receipt of the sample.